Boothbay Fund Management’s Acceleron Pharma XLRN Stock Holding History

Boothbay Fund Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-103	Closed	-$1.32M	–	1921
2020 Q4	$1.32M	Buy	+103	New	+$12.1K	0.05%	403
2020 Q3	–	Sell	-47	Closed	-$448K	–	1325
2020 Q2	$448K	Sell	47 -369	-89%	-$35.6K	0.03%	609
2020 Q1	$3.74M	Buy	+416	New	+$32.3K	0.31%	70
2019 Q1	–	Sell	-103	Closed	-$449K	–	926
2018 Q4	$449K	Buy	+103	New	+$5.15K	0.07%	289
2018 Q3	–	Sell	-192	Closed	-$932K	–	989
2018 Q2	$932K	Buy	+192	New	+$7K	0.08%	202

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boothbay Fund Management's XLRN Position: Q2 2020 in Review

Boothbay Fund Management sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 27,099 shares — an estimated $2.61M sold.

Boothbay Fund Management first reported a position in XLRN in Q1 2020 and held it in 1 quarter. The position peaked at $2.44M in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

Boothbay Fund Management reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
Boothbay Fund Management sold 27,099 Acceleron Pharma shares in Q2 2020, an estimated $2.61M.
Boothbay Fund Management first reported a position in Acceleron Pharma in Q1 2020 and held it in 1 quarter.
Boothbay Fund Management's Acceleron Pharma position peaked at $2.44M in Q1 2020.
242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on Boothbay Fund Management's 13F filing for Q2 2020, filed 14 Aug 2020.